Saturday 17 October 2026
Export REPL’s income statement to Excel — free account
Replimune Group, Inc.
REPL Healthcare Biotechnology
In the quarter to June 2026, EPS grew 24.2%, free cash flow grew 5.04% and total debt rose 52.6%, each against the same quarter a year earlier.
10.86
0.89
−7.57%
Follow REPL
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(96.24%) | (90.88%) | (107.88%) | (134.29%) | |
| (69.91%) | (67.19%) | (71.05%) | (82.28%) | ||
ROIC |
(2,164.42%) | (1,825.35%) | (8,036.55%) | (1,154.69%) | |
Return on Tangible Assets |
(104.97%) | (128.98%) | (134.24%) | (170.45%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | — | |
Free Cash Flow per Share |
(2.93) | (3.07) | (3.07) | (2.90) | |
Free Cash Flow |
(269.69) | (283.27) | (284.57) | (280.54) | |
Capital Expenditures |
(7.02) | (5.35) | (4.22) | (1.49) | |
| Other line items | |||||
Cash ROIC |
(41.08%) | (51.56%) | (52.67%) | (68.97%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | — | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(40.18) | (40.90) | (36.11) | (29.92) | |
Operating CF/Net income |
0.85 | 0.88 | 0.89 | 0.94 | |
Depreciation/Fixed assets |
(0.15) | (0.05) | 0.06 | 0.18 | |
Capex/Depreciation |
3.09 | 7.04 | (5.37) | (0.71) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(2.86) | (3.01) | (3.02) | (2.88) | |
Capex per Share |
(0.08) | (0.06) | (0.05) | (0.02) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates